Agomab Therapeutics To Present Open-Label Extension Data For Ontunisertib In Fibrostenosing Crohn's Disease At UEG Week On October 20
Share
Why It Matters
Agomab is sharing new test results for a Crohn's disease medicine. When companies show their work in public, people can see if the treatment is really helping patients.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.